Clinical trial recruitment for ABBV-744 study Fundamentals Explained
In Segment C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will get treatment until finally illness progression or maybe the participants are not able to tolerate the study drugs.Ubiquitin-associated proteins that control The steadiness of essential Tremendous